Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response With a Prior Course of Interferon Based Therapy
Brief Summary: The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a, Pegasys®), and Ribavirin (RBV, Copegus®) in people with genotype 1 hepatitis C who have not achieved a Sustained Viral Response (SVR) with a previous treatment of interferon therapy.


Options:
A: Arm Label: Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin (RBV) tablet | Arm Label: Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2b, Drug: Ribavirin (RBV) capsule | Arm Label: Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin (RBV) tablet | Arm Label: Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2b, Drug: Ribavirin (RBV) capsule | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule, Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule | Intervention Type: DRUG; Name: Peg-IFN-alfa-2a; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet | Intervention Type: DRUG; Name: Peg-IFN-alfa-2b; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule, Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule | Intervention Type: DRUG; Name: Ribavirin (RBV) tablet; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet | Intervention Type: DRUG; Name: Ribavirin (RBV) capsule; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule, Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule
B: Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a | Arm Label: Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a | Arm Label: Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Pegylated Interferon Alfa 2a | Arm Label: PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a, Drug: Matching Placebo | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week, Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: DRUG; Name: Pegylated Interferon Alfa 2a; Assigned to Arm(s): PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week, Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week
C: Arm Label: SOF+PEG+RBV 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Arm Label: SOF+PEG+RBV 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Arm Label: SOF+PEG+RBV 12 week/Rerandomization Group; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): SOF+PEG+RBV 12 week/Rerandomization Group, SOF+PEG+RBV 12 weeks, SOF+PEG+RBV 24 weeks | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+PEG+RBV 12 week/Rerandomization Group, SOF+PEG+RBV 12 weeks, SOF+PEG+RBV 24 weeks | Intervention Type: DRUG; Name: PEG; Assigned to Arm(s): SOF+PEG+RBV 12 week/Rerandomization Group, SOF+PEG+RBV 12 weeks, SOF+PEG+RBV 24 weeks
D: Arm Label: A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Placebo to Elbasvir, Drug: Ribavirin | Arm Label: A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Placebo to Elbasvir, Drug: Ribavirin | Arm Label: A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Arm Label: D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Ribavirin | Intervention Type: DRUG; Name: Grazoprevir; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk, B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk, B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk, B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk, D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | Intervention Type: DRUG; Name: Elbasvir; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk, B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk, B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk, B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk, B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk, C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk, D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | Intervention Type: DRUG; Name: Placebo to Elbasvir; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk, A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk, B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk, C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk, D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk, D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk

Answer: B